Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States.
Stoke Therapeutics Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$24.04|
|52 Week High||US$21.42|
|52 Week Low||US$71.58|
|1 Month Change||0.46%|
|3 Month Change||-27.92%|
|1 Year Change||-38.25%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-5.98%|
Recent News & Updates
We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
|STOK||US Biotechs||US Market|
Return vs Industry: STOK underperformed the US Biotechs industry which returned 10.6% over the past year.
Return vs Market: STOK underperformed the US Market which returned 24.8% over the past year.
Stable Share Price: STOK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: STOK's weekly volatility (8%) has been stable over the past year.
About the Company
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy.
Stoke Therapeutics Fundamentals Summary
|STOK fundamental statistics|
Is STOK overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|STOK income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.82|
|Net Profit Margin||0.00%|
How did STOK perform over the long term?See historical performance and comparison
Is Stoke Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate STOK's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate STOK's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: STOK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: STOK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate STOK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: STOK is overvalued based on its PB Ratio (3.5x) compared to the US Biotechs industry average (2.9x).
How is Stoke Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: STOK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: STOK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: STOK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: STOK is forecast to have no revenue next year.
High Growth Revenue: STOK is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: STOK is forecast to be unprofitable in 3 years.
How has Stoke Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: STOK is currently unprofitable.
Growing Profit Margin: STOK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: STOK is unprofitable, and losses have increased over the past 5 years at a rate of 52.8% per year.
Accelerating Growth: Unable to compare STOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: STOK has a negative Return on Equity (-26.27%), as it is currently unprofitable.
How is Stoke Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: STOK's short term assets ($260.2M) exceed its short term liabilities ($8.2M).
Long Term Liabilities: STOK's short term assets ($260.2M) exceed its long term liabilities ($1.2M).
Debt to Equity History and Analysis
Debt Level: STOK is debt free.
Reducing Debt: STOK has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: STOK has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: STOK has sufficient cash runway for 2.4 years if free cash flow continues to reduce at historical rates of 49.1% each year.
What is Stoke Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate STOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate STOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if STOK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if STOK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of STOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ed Kaye (72 yo)
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
CEO Compensation Analysis
Compensation vs Market: Ed's total compensation ($USD4.95M) is above average for companies of similar size in the US market ($USD2.28M).
Compensation vs Earnings: Ed's compensation has increased whilst the company is unprofitable.
Experienced Management: STOK's management team is considered experienced (2.3 years average tenure).
Experienced Board: STOK's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.6%.
Stoke Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: Stoke Therapeutics, Inc.
- Ticker: STOK
- Exchange: NasdaqGS
- Founded: 2014
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$883.448m
- Shares outstanding: 36.75m
- Website: https://www.stoketherapeutics.com
Number of Employees
- Stoke Therapeutics, Inc.
- 45 Wiggins Avenue
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/14 22:45|
|End of Day Share Price||2021/10/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.